GLAND.NS(GLAND.NS)
GLAND.NS
No analyst ratings available
No analyst price targets available for GLAND.NS
Analyst coverage may not be available for this symbol
No recent analyst actions
| Metric | FY2027E | FY2028E | FY2029E |
|---|---|---|---|
| Revenue Avg | $73.53B | $83.28B | $94.82B |
| Low | $71.18B | $76.18B | $94.79B |
| High | $76.45B | $88.46B | $94.85B |
| EBITDA Avg | $20.21B | $22.89B | $26.07B |
| Low | $19.57B | $20.94B | $26.06B |
| High | $21.02B | $24.32B | $26.08B |
| EBIT Avg | $16.50B | $18.68B | $21.27B |
| Low | $15.97B | $17.09B | $21.27B |
| High | $17.15B | $19.85B | $21.28B |
| Net Income Avg | $12.49B | $15.22B | $17.83B |
| Low | $11.27B | $13.29B | $14.85B |
| High | $13.26B | $16.83B | $21.09B |
| EPS Avg | $74.19 | $90.74 | $107.79 |
| Low | $68.34 | $80.59 | $90.00 |
| High | $80.41 | $102.06 | $127.83 |
| Analysts (Rev / EPS) | 13 / 13 | 14 / 13 | 7 / 6 |
| Metric | Q3 2026 | Q4 2026 | Q1 2027 |
|---|---|---|---|
| Revenue Avg | $17.46B | $19.40B | $19.18B |
| Low | $17.35B | $19.28B | $19.06B |
| High | $17.57B | $19.52B | $19.31B |
| EBITDA Avg | $4.80B | $5.33B | $5.27B |
| Low | $4.77B | $5.30B | $5.24B |
| High | $4.83B | $5.37B | $5.31B |
| EBIT Avg | $3.92B | $4.35B | $4.30B |
| Low | $3.89B | $4.33B | $4.28B |
| High | $3.94B | $4.38B | $4.33B |
| Net Income Avg | $2.46B | $3.06B | $3.11B |
| Low | $2.44B | $3.03B | $3.09B |
| High | $2.48B | $3.08B | $3.14B |
| EPS Avg | $14.89 | $18.55 | $18.86 |
| Low | $14.77 | $18.39 | $18.71 |
| High | $15.02 | $18.70 | $19.02 |
| Analysts (Rev / EPS) | 2 / 1 | 1 / 1 | 1 / 1 |